PCA3Prostate Cancer Antigen 3
References in periodicals archive ?
PCA3 is a urine sample collected after a DRE that calculates the ratio of PCA3 RNA molecules to PSA RNA molecules (Hessels et al.
under which Gen-Probe agreed to acquire all assets related to DiagnoCure's PCA3 prostate cancer biomarker for CDN 6,534,740.
The FDA's (Food and Drug Administration) recent Safety Alert regarding cybersecurity vulnerabilities in Hospira's PCA3 and PCA5 Infusion Pump Systems has caused the in-house counsel at many medical device companies to pause and ask, "Are we ready?
We use PCA3 for patients who come in before an initial biopsy with worrisome PSA levels, in the 3 to 7 [ng/mL] range, when we're not sure whether that indicates non-cancerous prostate enlargement or prostate cancer," Dr.
Several studies investigated the role of prostate cancer antigen 3 (PCA3) in the insignificant cancer diagnosis and some of them demonstrated a significant correlation between PCA3 score and tumor volume [123,124], extraprostatic extension [125], and Gleason score [8].
The company offers variety of tests such as hematuria assessment, molecular grading, recurrence monitoring, urine cytology, urovysion, prostate biopsy complete evaluation, prostate biopsies, histology / anatomic pathology and PCA3.
1 million, chiefly as a result of a milestone payment made by US Hologic Gen-Probe, which holds the global exclusive licence for the development and marketing of a prostate cancer test, Progensa PCA3, using DiagnoCure's molecular biomarker PCA3.
A plethora of promising blood- and urine-based biomarkers have shown promise in early studies and are at various stages of development (Human kallikrein 2, Early Prostate Cancer Antigen, Transforming Growth Factor-Beta 1 and Interleukin-6, Endoglin, PCA3, AMACR and ETS Gene Fusions).
But because the gene fusion is present only half the time, the researchers also included another marker, PCA3.